Understanding Breast cancer: from conventional therapies to repurposed drugs

Costa, Bárbara; Amorim, Irina; Gärtner, Fátima; Vale, Nuno

doi:10.1016/j.ejps.2020.105401

Cited by 49 publications

(28 citation statements)

References 286 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activation of PI3K/AKT has been related to breast cancer, and currently, there is much interest in the development of inhibitors of this pathway to target breast cancer. 23 In addition, PI3K/AKT/mTOR pathway upregulation has been linked to chemotherapy and radiotherapy resistance, 24 and its inhibition overcomes drug resistance in breast cancer cells. 25 , 26 Another pathway suggested by our analysis was the MAPK pathway.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers

Barrón‐Gallardo

García‐Chagollán

Morán-Mendoza

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Worldwide breast cancer ranks first in mortality and incidence rates in women over 20 years old. Rather than one disease, breast cancer is a heterogeneous group of diseases that express distinct molecular profiles. Neoadjuvant chemotherapy is an important therapeutic strategy for breast cancer patients independently of their molecular subtype, with the drawback of resistance development. In addition, chemotherapy has adverse effects that combined with resistance could contribute to lower overall survival. Although great efforts have been made to find diagnostic and prognostic biomarkers for breast cancer and for response to targeted and immune therapy for this pathology, little has been explored regarding biomarkers of response to anthracyclines and taxanes based neoadjuvant chemotherapy. This work aimed to evaluate the molecular profile of patients who received neoadjuvant chemotherapy to identify differentially expressed genes (DEGs) that could be used as biomarkers of chemotherapy response and overall survival. Breast cancer patients who were candidates for neoadjuvant chemotherapy were enrolled in this study. After treatment and according to their pathological response, they were assigned as sensitive or resistant. To evaluate DEGs, Gene Ontology, Kyoto Encyclopedia Gene and Genome (KEGG), and protein–protein interactions, RNA-seq information from all patients was obtained by next-generation sequencing. A total of 1985 DEGs were found, and KEGG analysis indicated a great number of DEGs in metabolic pathways, pathways in cancer, cytokine–cytokine receptor interactions, and neuroactive ligand-receptor interactions. A selection of 73 DEGs was used further for an analysis of overall survival using the METABRIC study and the ductal carcinoma dataset of The Cancer Genome Atlas (TCGA) database. Nine DEGs correlated with overall survival, of which the subexpression of C1QTNF3, CTF1, OLFML3, PLA2R1, PODN, KRT15, HLA-A, and the overexpression of TUBB and TCP1 were found in resistant patients and related to patients with lower overall survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers

Barrón‐Gallardo

García‐Chagollán

Morán-Mendoza

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…One of these was the PI3K/AKT pathway which can induce mTOR (mammalian Target of Rapamycin) stimulation leading to sustained proliferative signals. Activation of PI3K/AKT has been related to breast cancer and currently, there is a lot of interest in the development of inhibitors of this pathway to target breast cancer 14 . Besides, PI3K/AKT/mTOR pathway upregulation has been linked to chemotherapy and radiotherapy resistance 15 and its inhibition overcome drug resistance in breast cancer cells 16,17 .…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic analysis of breast cancer patients sensitive and resistant to chemotherapy: Looking for overall survival and drug resistance biomarkers

Barrón‐Gallardo

García‐Chagollán

Morán-Mendoza

et al. 2020

Preprint

View full text Add to dashboard Cite

Neoadjuvant chemotherapy is one important therapeutic strategy for breast cancer with the drawback of resistance development. Chemotherapy has adverse effects that combined with resistance could contribute to lower overall survival. This work aimed to evaluate the molecular profile of patients who received neoadjuvant chemotherapy to discover differentially expressed genes (DEGs) that could be used as biomarkers of chemotherapy response and overall survival. Breast cancer patients who received neoadjuvant chemotherapy were enrolled in this study and according to their pathological response were assigned as sensitive or resistant. To evaluate DEGs, GO, KEGG, and protein-protein interactions, RNAseq information from all patients was obtained by next-generation sequencing. A total of 1985 DEGs were found and KEGG analysis indicated a great number of DEGs in metabolic pathways, pathways in cancer, cytokine-cytokine receptor interactions, and neuroactive ligand-receptor interactions. A selection of 73 DEGs was used further for an analysis of overall survival using the METABRIC study. Seven of those DEGs correlated with overall survival, of them the sub-expression of C1QTNF3, CTF1, OLFML3, PLA2R1, PODN and the over expression of TUBB and TCP1 were found in resistant patients and related to patients with lower overall survival.

show abstract

“…A miRNA-mediated PI3K pathway serves a central role in trastuzumab resistance (83). PI3K pathway inhibitors resulted in reduced miR30b expression and re-sensitization to trastuzumab in the trastuzumab resistant HCC1954 cells (84).…”

Section: Role Of Mir-30b In Breast Cancermentioning

confidence: 99%

Roles and regulatory mechanisms of miR‑30b in cancer, cardiovascular disease, and metabolic disorders (Review)

et al. 2020

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are non-coding RNAs 21-23 nucleotides in length that regulate gene expression, and thereby modulate signaling pathways and protein synthesis in both physiological and pathogenic processes. miR-30b inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transformation in multiple types of cancer. In addition to its role in several types of neoplasias, miR-30b has been shown to exhibit essential roles in cardiovascular and metabolic diseases. In the present review, an overview of the biological functions of miR-30b and its role in the pathogenesis of neoplastic, cardiovascular and metabolic diseases is provided. miR-30b is a potential candidate for clinical development as a diagnostic and prognostic biomarker, therapeutic agent and drug target. However, further research is required to elucidate its role in health and disease and to harness its potential clinical utility.

show abstract

Understanding Breast cancer: from conventional therapies to repurposed drugs

Cited by 49 publications

References 286 publications

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers

Transcriptomic analysis of breast cancer patients sensitive and resistant to chemotherapy: Looking for overall survival and drug resistance biomarkers

Roles and regulatory mechanisms of miR‑30b in cancer, cardiovascular disease, and metabolic disorders (Review)

Contact Info

Product

Resources

About